Genomics

Dataset Information

0

Oridonin delays aging through AKT signaling pathway


ABSTRACT: Aging is the major risk factor for chronic diseases and disability in human. There is no effective anti-aging clinical treatment. In this study, oridonin was selected based on the drug screening strategy of Connectivity MAP (CMAP) upon transcriptomes of 102 traditional Chinese medicines (TCM) treated cell lines. Oridonin is an anti-inflammatory drug and diterpenoid isolated from Rabdosia rubescens. Oridonin exhibited a variety of pharmacological activities, including anti-tumor, antibacteria and anti-inflammation. Here, we found that oridonin inhibited cellular senescence in human diploid fibroblasts (2BS and WI-38), indicated by decreased senescence-associated β-galactosidase (SA-β-gal) staining. Compared with the elderly control group, the positive cell rate in the oridonin intervention group was 48.5%, and the cell shape was similar to young cells. Oridonin prolonged the lifespan of yeast by 14.6%~48.9%, and prolonged the average life span of naturally aged mice by 21.6%. It also increased the healthspan of aged mice. In addition, oridonin also improved doxorubicin-induced cellular senescence and mouse senescence. Compared with the model group, the percentage of SA-β-gal positive cells in the oridonin treatment group was reduced to 59.8%. It prolonged the average life span of mice by 53.8% as well as the healthspan. Mechanistically, we show that oridonin delayed aging through the AKT signaling pathways and reverses the genetic changes caused by doxorubicin-induced cell senescence. Therefore, oridonin may be an ideal candidate for the development of anti-aging drugs, and it also provides therapeutic potential in other diseases.

ORGANISM(S): Homo sapiens

PROVIDER: GSE189789 | GEO | 2022/03/18

REPOSITORIES: GEO

Similar Datasets

2021-10-08 | GSE185416 | GEO
2021-10-01 | GSE179880 | GEO
| E-GEOD-41714 | biostudies-arrayexpress
2023-10-30 | GSE216516 | GEO
2013-04-24 | GSE41714 | GEO
2021-03-06 | GSE168322 | GEO
2023-10-30 | GSE186887 | GEO
2019-08-20 | GSE115227 | GEO
2017-11-06 | PXD006216 | Pride
2021-06-17 | GSE112530 | GEO